No Data
ANI Pharmaceuticals (NASDAQ:ANIP): Strongest Q3 Results From the Generic Pharmaceuticals Group
Investing in ANI Pharmaceuticals (NASDAQ:ANIP) Three Years Ago Would Have Delivered You a 53% Gain
ANI Pharmaceuticals to Present at the Guggenheim Biotech Conference
Raymond James Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Maintains Target Price $83
ANI Pharmaceuticals (ANIP) Receives a Buy From Raymond James
Revenues Working Against ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Share Price
ANI Pharmaceuticals (NASDAQ:ANIP) Delivers Shareholders Respectable 19% CAGR Over 3 Years, Surging 5.9% in the Last Week Alone
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
